(Q38431284)

3 September 2017

1 reference

title

Clinical management of breast cancer heterogeneity (English)

1 reference

3 September 2017

1 reference

1 reference

Charles Swanton

3

0 references

author name string

Dimitrios Zardavas

series ordinal

1

1 reference

3 September 2017

Alexandre Irrthum

series ordinal

2

1 reference

3 September 2017

Martine Piccart

series ordinal

4

1 reference

3 September 2017

language of work or name

English

0 references

publication date

21 April 2015

1 reference

Nature Reviews Clinical Oncology

3 September 2017

1 reference

3 September 2017

12

1 reference

3 September 2017

7

1 reference

3 September 2017

381-394

1 reference

Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years

3 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Grade and flow cytometric analysis of ploidy for infiltrating ductal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Gene-expression signatures in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Insight into the heterogeneity of breast cancer through next-generation sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Next-generation sequencing in breast cancer: first take home messages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Tumour heterogeneity in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

The causes and consequences of genetic heterogeneity in cancer evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Intratumor heterogeneity: seeing the wood for the trees.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

The patterns and dynamics of genomic instability in metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

The seed and soil hypothesis revisited: current state of knowledge of inherited genes on prognosis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Gene expression profiling of the tumor microenvironment during breast cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Emerging targeted agents in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Personalized therapy for breast cancer: a dream or a reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

A unifying theory of carcinogenesis, and why targeted therapy doesn't work.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Myoepithelial and epithelial-myoepithelial, mesenchymal and fibroepithelial breast lesions: updates from the WHO Classification of Tumours of the Breast 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Clinical characteristics of different histologic types of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Molecular alterations in metaplastic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Survival outcomes of metaplastic breast cancer patients: results from a US population-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Luminal B breast cancer: molecular characterization, clinical management, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Identification of molecular apocrine breast tumours by microarray analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

The rebel angel: mutant p53 as the driving oncogene in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Mutation of GATA3 in human breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Sequence analysis of mutations and translocations across breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Direct evidence for concurrent morphological and genetic heterogeneity in an invasive ductal carcinoma of triple-negative phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Inferring tumor progression from genomic heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Evolution of the cancer genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Mutational processes molding the genomes of 21 breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

The life history of 21 breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

The AURORA initiative for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Ductal Carcinoma in Situ of the Breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Molecular evolution of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

PIK3CA mutations in in situ and invasive breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Genome remodelling in a basal-like breast cancer metastasis and xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Tumour evolution inferred by single-cell sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Clonal evolution in breast cancer revealed by single nucleus genome sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Detection of ultra-rare mutations by next-generation sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Cancer: One cell at a time

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Breast cancer: origins and evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Tumour heterogeneity and cancer cell plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

The clonal evolution of tumor cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Influence of tumour micro-environment heterogeneity on therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Breast cancer genome heterogeneity: a challenge to personalised medicine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Molecular characterization of clonal interference during adaptive evolution in asexual populations of Saccharomyces cerevisiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Pervasive genetic hitchhiking and clonal interference in forty evolving yeast populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Circulating tumour cells and cell-free DNA as tools for managing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Addressing genetic tumor heterogeneity through computationally predictive combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Intratumor heterogeneity alters most effective drugs in designed combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Absolute quantification of somatic DNA alterations in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

A census of human cancer genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Misfolded proteins impose a dosage-dependent fitness cost and trigger a cytosolic unfolded protein response in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Impact of deleterious passenger mutations on cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Paradoxical relationship between chromosomal instability and survival outcome in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Aneuploidy drives genomic instability in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Clonal competition with alternating dominance in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Tracking the clonal origin of lethal prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Metronomic chemotherapy: new rationale for new directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Metronomics: towards personalized chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Metronomic therapy and breast cancer: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Evolutionary approaches to prolong progression-free survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Accessories to the crime: functions of cells recruited to the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

A DNA-Binding Protein Helps Repair Breaks in DNA Double Helix

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Stromal gene expression predicts clinical outcome in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

A leukotriene B4 receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Targeting the tumor microenvironment: from understanding pathways to effective clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Liquid biopsy: monitoring cancer-genetics in the blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Challenges in circulating tumour cell research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Molecular analysis of circulating tumour cells-biology and biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Analysis of circulating tumor DNA to monitor metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Integrative mathematical oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Dissecting cancer through mathematics: from the cell to the animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Clinically relevant modeling of tumor growth and treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Cancer Systems Biology: a peek into the future of patient care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Combined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Defining principles of combination drug mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

One mouse, one patient paradigm: New avatars of personalized cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

The landscape of cancer genes and mutational processes in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

How does the extracellular matrix direct gene expression?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

The mutational meltdown in asexual populations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Anticancer drug development: moving away from the old habits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Biology-driven phase II trials: what is the optimal model for molecular selection?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Mouse hospital and co-clinical trial project--from bench to bedside.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Whole-genome analysis informs breast cancer response to aromatase inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Change of HER-2/neu status in a subset of distant metastases from breast carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Estrogen and progesterone receptor concordance between primary and recurrent breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.73

Rationale for the use of alternating non-cross-resistant chemotherapy.

31 March 2020

1 reference

12 December 2020

The Norton-Simon hypothesis revisited

1 reference

12 December 2020

Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity.

1 reference

12 December 2020

Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems

1 reference

12 December 2020

A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate

1 reference

12 December 2020

The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity

1 reference

12 December 2020

Grouping of molecularly targeted anti-cancer agents based on cost-effectiveness analysis

1 reference

12 December 2020

A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer

1 reference

12 December 2020

Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer.

1 reference

12 December 2020

Tumor size, sensitivity to therapy, and design of treatment schedules

1 reference

12 December 2020

10.1038/NRCLINONC.2015.73

Identifiers

DOI

1 reference

3 September 2017

1 reference